STOCK TITAN

Equillium (EQ) SEC Filings, Jan-Mar 2026

EQ NASDAQ

Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.

Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.

Rhea-AI Summary

Form 144 notice: Christine Zedelmayer submitted a Rule 144 notice reporting proposed sales of Common Stock. The filing lists a proposed sale quantity of 120,312 shares dated 03/13/2026, and shows prior reported dispositions of 11,900 shares on 12/15/2025, 185,937 shares on 02/19/2026, and 181,219 shares on 03/09/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.07%
Tags
other
-
Rhea-AI Summary

Equillium, Inc. entered into a private placement with RA Capital Healthcare Fund to raise approximately $35.0 million through common stock and a pre-funded warrant. The company will sell 1,179,508 shares at $1.854 per share and a pre-funded warrant for up to 17,698,593 shares at $1.8539 per warrant share, with an exercise price of $0.0001 per share. The warrant is exercisable immediately on a cash or cashless basis, subject to a beneficial ownership cap of 19.99%. Equillium plans to use the net proceeds, together with existing cash, to fund development of EQ504 and for working capital and general corporate purposes. The company will also grant the investor registration rights to resell the shares and warrant shares, subject to potential cash penalties if registration obligations are not met.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.32%
Tags
current report
-
Rhea-AI Summary

Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sell set of transactions in company common stock. On February 19, 2026, she exercised options to acquire a total of 185,937 shares of common stock at prices of $0.785 and $0.73 per share.

On the same date, she sold the same 185,937 shares in open-market transactions at average prices of about $1.78 per share. After these trades, she directly held 91,444 shares of Equillium common stock. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025, indicating they were pre-arranged rather than timed discretionarily.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
insider
Rhea-AI Summary

Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised stock options and sold shares in a planned transaction. On March 9, 2026 she exercised options for a total of 152,361 shares of common stock at an exercise price of $0.785 per share.

The same day she sold 181,219 shares of common stock at a weighted average price of $2.00 per share, with individual sale prices ranging from $2.00 to $2.015, under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions she directly owned 62,586 shares of Equillium common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
insider
-
Rhea-AI Summary

Equillium, Inc. officer Christine Zedelmayer submitted notice of a proposed sale of 181,219 shares of common stock, with an aggregate market value of $320,757 and an approximate sale date of March 9, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
other
-
Rhea-AI Summary

Equillium, Inc. executive Christine Zedelmayer reported option exercises and related share sales in a Form 4. On February 19, 2026, she exercised employee stock options covering 109,375 and 76,562 shares, converting them into common stock at stated exercise prices.

On the same date, she sold 109,375 shares at $1.7814 per share and 76,562 shares at $1.7406 per share in open-market transactions. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions, she directly owned 191,444 shares of Equillium common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
insider
Rhea-AI Summary

Equillium, Inc. officer Christine Zedelmayer reported a proposed sale of 185,937 common shares, with an aggregate market value of $316,092 and an approximate sale date of February 19, 2026. The listed acquisition entries show 109,375 shares acquired from the issuer through stock options on January 12, 2022, and 76,562 on January 2, 2024; both list cash as the nature of payment. The Rule 10b5-1 section gives August 27, 2025 as the plan-adoption or instruction date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.40%
Tags
other
-
Rhea-AI Summary

Janus Henderson Group plc has filed an amended Schedule 13G reporting beneficial ownership of 6,083,239 shares of Equillium, Inc. common stock, representing 9.99% of the class. These holdings are managed through various affiliated asset managers on behalf of client accounts, called Managed Portfolios.

The position includes shares that may be obtained through exercise of certain pre-funded warrants that are exercisable within 60 days, but only to the extent total beneficial ownership does not exceed 9.99% of Equillium’s outstanding common stock. An additional 18,584,856 warrants are excluded from the reported figures due to this ownership cap. Dividends and sale proceeds belong to the Managed Portfolios, not Janus Henderson.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
ownership
-
Rhea-AI Summary

Equillium, Inc. granted its President and Chief Scientific Officer, Stephen Connelly, an employee stock option to buy 1,150,000 shares of common stock at an exercise price of $1.31 per share on 01/07/2026. The option has an expiration date of 01/06/2036 and was received at no cost, as reflected by a derivative security price of $0.

According to the vesting terms, 25% of the shares under the option vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Connelly beneficially holds 1,150,000 stock options directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
Rhea-AI Summary

Equillium, Inc. reported that Sr. Vice President and COO Christine Zedelmayer received an employee stock option grant on 01/07/2026. The derivative award covers 500,000 stock options with an exercise price of $1.31 per share, allowing her to buy common stock at that price in the future. The grant was reported at a cost of $0 for the option itself and leaves her with 500,000 derivative securities beneficially owned directly after the transaction.

According to the vesting terms, 25% of the option vests on the first anniversary of the vesting commencement date, and the remaining options vest in 36 equal monthly installments over the following three years, resulting in a standard four-year vesting schedule tied to ongoing service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider

FAQ

How many Equillium (EQ) SEC filings are available on StockTitan?

StockTitan tracks 72 SEC filings for Equillium (EQ), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Equillium (EQ)?

The most recent SEC filing for Equillium (EQ) was filed on November 13, 2026.